Phytopharmaceuticals in India: A case for perpetual ‘New Drug’-style regulation over ASU-style liberalisation and counterproductive genericisation. Read more
Clinical exclusivity for indigenous medicines can improve long-term affordability and access Read more
India’s upcoming semaglutide boom: A turning point for GLP‑1 drugs, pricing and patient access Read more